Approval · Notice of Compliance 2371 · 2001
LYMERIX: Notice of Compliance 2371
Issued July 20, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2371
- Date
- July 20, 2001
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Change in manufacturer name
- Therapeutic class
- Immunizing agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LYMERIX | 02239195 | Cancelled Post Market |
Medicinal ingredients
- LIPOPROTEIN OSPA 30 MCG per 0.5ML